Repair Biotechnologies
Syracuse, US · Founded 2018 · Delaware corporation · 2 known investors
Repair Biotechnologies develops the Cholesterol Degrading Platform, a therapeutic approach for treating conditions caused by localized accumulations of excess cholesterol. Its lead application aims to reduce atherosclerotic plaque in arteries to address cardiovascular diseases such as stroke and heart attack.
Founders & leadership
Repair Biotechnologies was founded in 2018 by Guilherme Cherman Perdigao de Oliveira and Reason.
GC
Guilherme Cherman Perdigao de OliveiraCo-founder
R
Reason"CEO's full legal name is ""Reason"""
AM
Anthony Matthew ChowNamed on SEC filing
Board
KM
Kelsey MoodyBoard director
Investors · 2
Reported raises · per SEC filings
Form D private placements$25.5M disclosed across 8 rounds · 2018–2025
▶$5.3MraisedNov 2025 · 16 investors · BiotechnologyRule 506(b)
▶$5.3MraisedNov 2025 · 16 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Guilherme Cherman Perdigao de OliveiraExecutive Officer, Director
- Kelsey MoodyDirector
- ReasonExecutive Officer, Director
- Offering amount
- $11M
- Amount sold
- $5.3M
- Proceeds to insiders
- $150K
- First sale
- Nov 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$6.2MraisedMar 2024 · 7 investors · BiotechnologyRule 506(b)
▶$6.2MraisedMar 2024 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Kelsey MoodyDirector
- ReasonExecutive Officer, Director
- Guilherme Cherman Perdigao de OliveiraExecutive Officer, Director
- Offering amount
- $50M
- Amount sold
- $6.2M
- Proceeds to insiders
- $150K
- First sale
- Mar 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$8.4MraisedJun 2023 · 38 investors · BiotechnologyRule 506(b)
▶$8.4MraisedJun 2023 · 38 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Kelsey MoodyDirector
- ReasonExecutive Officer, Director
- Guilherme Cherman Perdigao de OliveiraExecutive Officer, Director
- Offering amount
- $8.6M
- Amount sold
- $8.4M
- Proceeds to insiders
- $150K
- First sale
- Jun 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$200KraisedFeb 2021 · 2 investors · BiotechnologyRule 506(b)
▶$200KraisedFeb 2021 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Guilherme Cherman Perdig?o de OliveiraDirector
- ReasonExecutive Officer, Director
- Amount sold
- $200K
- Proceeds to insiders
- $150K
- First sale
- Feb 2021
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$2.9MraisedSep 2020 · 13 investors · BiotechnologyRule 506(b)
▶$2.9MraisedSep 2020 · 13 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Anthony Matthew ChowDirector
- ReasonExecutive Officer, Director
- Guilherme Cherman Perdig?o de OliveiraDirector
- Offering amount
- $3.8M
- Amount sold
- $2.9M
- Proceeds to insiders
- $150K
- First sale
- Aug 2020
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$2.1MraisedMay 2019 · 15 investors · BiotechnologyRule 506(b)
▶$2.1MraisedMay 2019 · 15 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- ReasonExecutive Officer, Director
- Guilherme Cherman Perdigao de OliveiraDirector
- Anthony Matthew ChowDirector
- Amount sold
- $2.1M
- Proceeds to insiders
- $150K
- First sale
- Mar 2019
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$75KraisedJan 2019 · 1 investors · BiotechnologyRule 506(b)
▶$75KraisedJan 2019 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- ReasonExecutive Officer
- Offering amount
- $75K
- Amount sold
- $75K
- Proceeds to insiders
- $50K
- First sale
- Jan 2019
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$450KraisedAug 2018 · 6 investors · BiotechnologyRule 506(b)
▶$450KraisedAug 2018 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- ReasonExecutive Officer
- Offering amount
- $550K
- Amount sold
- $450K
- Proceeds to insiders
- $22K
- First sale
- Jul 2018
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlap
Doximity12 shared keywordsDoximity is the largest verified network of healthcare professionals in the U.S., connecting physicians, PAs, NPs, pharmacists, and medical students across specialties and care settings. The platform provides mobile-first tools for clinical communication, collaboration, and workflow optimization.
Practo7 shared keywordsPracto operates an online healthcare platform offering a directory of verified doctors, appointment booking at hospitals and clinics, online consultations across 20+ specialities, subscription health plans, diagnostic test collection, and medicine delivery. It also provides practice management and hospital information management software for clinics and hospitals.
Companies competing with Repair Biotechnologies for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Repair Biotechnologies do?
- Repair Biotechnologies develops the Cholesterol Degrading Platform, a therapeutic approach for treating conditions caused by localized accumulations of excess cholesterol. Its lead application aims to reduce atherosclerotic plaque in arteries to address cardiovascular diseases such as stroke and heart attack.
- Who founded Repair Biotechnologies?
- Repair Biotechnologies was founded by Guilherme Cherman Perdigao de Oliveira, Reason in 2018.
- Who are Repair Biotechnologies's investors?
- Repair Biotechnologies's investors include quadraScope Venture Fund, Thynk Capital.
- How much funding has Repair Biotechnologies raised?
- Repair Biotechnologies has disclosed $25.5M raised across 8 rounds.
- Where is Repair Biotechnologies headquartered?
- Repair Biotechnologies is headquartered in Syracuse, US.